Page 644 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

622 PART IV Specific Malignancies in the Small Animal Patient

75. Mainenti M, Rasotto R, Carnier P, et al.: OEstrogen and progester- 94. Sassi F, Benazzi C, Castellani G, et al.: Molecular-based tumour
one receptor expression in subtypes of canine mammary tumours subtypes of canine mammary carcinomas assessed by immunohis-
in intact and ovariectomised dogs, Vet J 202:62–68, 2014. tochemistry, BMC Vet Res 6(5), 2010.
VetBooks.ir 76. Chang CC, Tsai MH, Liao JW, et al.: Evaluation of hormone 95. Pena L, Gama A, Goldschmidt MH, et al.: Canine mammary
tumors: a review and consensus of standard guidelines on epithelial
receptor expression for use in predicting survival of female dogs
with malignant mammary gland tumors, J Am Vet Med Assoc
235:391–396, 2009. and myoepithelial phenotype markers, HER2, and hormone recep-
tor assessment using immunohistochemistry, Vet Pathol 51:127–
77. Nieto A, Pena L, Perez-Alenza MD, et al.: Immunohistologic detec- 145, 2014.
tion of estrogen receptor alpha in canine mammary tumors: clinical 96. The Cancer Genome Atlas Network: Comprehensive molecular
and pathologic associations and prognostic significance, Vet Pathol portraits of human breast tumours, Nature 490:61–70, 2012.
37:239–247, 2000. 97. Sørlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns
78. Geraldes M, Gartner F, Schmitt F: Immunohistochemical study of breast carcinomas distinguish tumor subclasses with clinical
of hormonal receptors and cell proliferation in normal canine implications, Proc Natl Acad Sci USA 98:10869–10874, 2001.
mammary glands and spontaneous mammary tumours, Vet Rec 98. Malhotra GK, Zhao X, Band H, et al.: Histological, molecular and
146:403–406, 2000. functional subtypes of breast cancers, Cancer Biol Ther 10:955–
79. Kristiansen VM, Pena L, Diez Cordova L, et al.: Effect of ovar- 960, 2010.
iohysterectomy at the time of tumor removal in dogs with mam- 99. Coleman WB, Anders CK: Discerning clinical responses in breast
mary carcinomas: a randomized controlled trial, J Vet Intern Med cancer based on molecular signatures, Am J Pathol 187:2199–2207,
30:230–241, 2016. 2017.
80. Effects of chemotherapy and hormonal therapy for early breast 100. Yam C, Mani SA, Moulder SL: Targeting the molecular subtypes of
cancer on recurrence and 15–year survival: an overview of the ran- triple negative breast cancer: understanding the diversity to prog-
domised trials, Lancet 365:1687–1717, 2005. ress the field, Oncologist 22:1086–1093, 2017.
81. Winer EP, Hudis C, Burstein HJ, et al.: American Society of 101. Perez Alenza MD, Tabanera E, Pena L: Inflammatory mammary
Clinical Oncology technology assessment on the use of aromatase carcinoma in dogs: 33 cases (1995–1999), J Am Vet Med Assoc
inhibitors as adjuvant therapy for postmenopausal women with 219:1110–1114, 2001.
hormone receptor-positive breast cancer: status report 2004, J Clin 102. Marconato L, Romanelli G, Stefanello D, et al.: Prognostic factors
Oncol 23:619–629, 2005. for dogs with mammary inflammatory carcinoma: 43 cases (2003–
82. Network NCC: Clinical practice guidelines in oncology - version 2008), J Am Vet Med Assoc 235:967–972, 2009.
2.2006, National Comprehensive Cancer Network, Inc., 2005. 103. Soultani C, Patsikas MN, Karayannopoulou M, et al.: Assess-
83. Tamoxifen for early breast cancer: An overview of the randomised ment of sentinel lymph node metastasis in canine mammary gland
trials. Early breast cancer trialists’ collaborative group, Lancet tumors using computed tomographic indirect lymphography, Vet
351:1451–1467, 1998. Radiol Ultrasound 58:186–196, 2017.
84. Thuerlimann B, Koeberle D, Senn HJ: Guidelines for the adjuvant 104. Pereira CT, Luiz Navarro Marques F, Williams J, et al.: MTC-
99
treatment of postmenopausal women with endocrine-responsive labeled dextran for mammary lymphoscintigraphy in dogs, Vet
breast cancer: past, present and future recommendations, Eur J Radiol Ultrasound 49:487–491, 2008.
Cancer 43:46–52, 2007. 105. MacEwen EG: Spontaneous tumors in dogs and cats: models for
85. Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for pre- the study of cancer biology and treatment, Cancer Metastasis Rev
vention of breast cancer: report of the National Surgical Adjuvant 9:125–136, 1990.
Breast and Bowel Project P-1 study, J Natl Cancer Inst 90:1371– 106. Vail DM, MacEwen EG: Spontaneously occurring tumors of com-
1388, 1998. panion animals as models for human cancer, Cancer Invest 18:781–
86. Sjogren S, Inganas M, Lindgren A, et al.: Prognostic and predic- 792, 2000.
tive value of c-erbb-2 overexpression in primary breast cancer, alone 107. Tuohy JL, Milgram J, Worley DR, et al.: A review of sentinel lymph
and in combination with other prognostic markers, J Clin Oncol node evaluation and the need for its incorporation into veterinary
16:462–469, 1998. oncology, Vet Comp Oncol 7:81–91, 2009.
87. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: 108. Gelb HR, Freeman LJ, Rohleder JJ, et al.: Feasibility of contrast-
correlation of relapse and survival with amplification of the HER-2/ enhanced ultrasound-guided biopsy of sentinel lymph nodes in
neu oncogene, Science 235:177–182, 1987. dogs, Vet Radiol Ultrasound 51:628–633, 2010.
88. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy 109. Pinheiro LG, Oliveira Filho RS, Vasques PH, et al.: Hemosiderin:
plus a monoclonal antibody against her2 for metastatic breast can- a new marker for sentinel lymph node identification, Acta Cir Bras
cer that overexpresses HER2, N Engl J Med 344:783–792, 2001. 24:432–436, 2009.
89. Martin de las Mulas J, Ordas J, Millan Y, et al.: Oncogene HER- 110. Balogh L, Thuroczy J, Andocs G, et al.: Sentinel lymph node detec-
2 in canine mammary gland carcinomas: an immunohistochemi- tion in canine oncological patients, Nucl Med Rev Cent East Eur
cal and chromogenic in situ hybridization study, Breast Cancer Res 5:139–144, 2002.
Treat 80:363–367, 2003. 111. Patsikas MN, Papadopoulou PL, Charitanti A, et al.: Computed
90. Hsu WL, Huang HM, Liao JW, et al.: Increased survival in dogs tomography and radiographic indirect lymphography for visualiza-
with malignant mammary tumours overexpressing HER-2 protein tion of mammary lymphatic vessels and the sentinel lymph node in
and detection of a silent single nucleotide polymorphism in the normal cats, Vet Radiol Ultrasound 51:299–304, 2010.
canine her-2 gene, Vet J 180:116–123, 2009. 112. Pereira CT, Rahal SC, de Carvalho Balieiro JC, et al.: Lymphatic
91. Gama A, Alves A, Schmitt F: Identification of molecular pheno- drainage on healthy and neoplasic mammary glands in female
types in canine mammary carcinomas with clinical implications: dogs: can it really be altered? Anat Histol Embryol 32:282–290,
application of the human classification, Virchows Arch 453:123– 2003.
132, 2008. 113. Patsikas MN, Dessiris A: The lymph drainage of the mammary
92. Im KS, Kim IH, Kim NH, et al.: Breed-related differences in glands in the bitch: a lymphographic study. Part II: the 3rd mam-
altered BRCA1 expression, phenotype and subtype in malignant mary gland, Anat Histol Embryol 25:139–143, 1996.
canine mammary tumors, Vet J 195:366–372, 2013. 114. Ran S, Volk L, Hall K, et al.: Lymphangiogenesis and lymphatic
93. Rungsipipat A, Tateyama S, Yamaguchi R, et al.: Immunohisto- metastasis in breast cancer, Pathophysiology 17:229–251, 2010.
chemical analysis of c-yes and c-erbb-2 oncogene products and p53 115. Wong JH, Cagle LA, Morton DL: Lymphatic drainage of skin to
tumor suppressor protein in canine mammary tumors, J Vet Med a sentinel lymph node in a feline model, Ann Surg 214:637–641,
Sci 61:27–32, 1999. 1991.